GlassScriptPhysician profile
Felicia Relkin
NPI 1720089303
$793.79
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $142.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $126.88 | 2019-2020 | |
| Amgen INC. | $115.71 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $70.32 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $57.60 | 2019 | |
| Abbvie INC. | $48.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $44.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.04 | 2019-2020 | |
| Glaxosmithkline, LLC. | $42.03 | 2019-2020 | |
| Novo Nordisk INC | $40.81 | 2019 | |
| Philips North America LLC | $35.84 | 2019 | |
| Allergan, INC. | $30.88 | 2019-2020 | |
| Redhill Biopharma INC. | $24.37 | 2020 | |
| Ironwood Pharmaceuticals, INC | $23.67 | 2019-2020 | |
| Lilly USA, LLC | $22.29 | 2019 | |
| Amarin Pharma, INC. | $15.00 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.61 | 2020 | |
| Jazz Pharmaceuticals INC. | $13.37 | 2019 | |
| Shire North American Group INC | $12.56 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felicia Relkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.